Skip to main content
. 2019 Dec 18;9:19356. doi: 10.1038/s41598-019-55833-0

Table 2.

Baseline characteristics of participants.

Characteristics All (n = 320) Female (n = 154) Male (n = 166)
Age (years) 55 ± 16.4 52 ± 15.3 57 ± 13.8
Weight (kg) 50.5 ± 13.8 48 ± 12.1 53 ± 14.5
Height (m) 1.65 ± 0.2 1.57 ± 0.1 1.68 ± 0.2
BMI (kg/m2) 21.6 ± 3.1 18.8 ± 1.3 20.3 ± 3.6
BSA (m2) 1.68 ± 0.2 1.63 ± 0.2 1.72 ± 0.2
Muscle mass (kg) 22.5 ± 5.8 19.8 ± 3.8 21.9 ± 10.8
Soft lean mass (kg) 39.6 ± 8.7 38.6 ± 4.4 41.3 ± 8.0
Body fat mass (kg) 10.4 ± 9.6 10.7 ± 8.1 11.8 ± 4.2
Fat free mass (kg) 41.3 ± 7.3 40.8 ± 2.7 41.4 ± 7.7
Proteinuria (g/day) 0.42 ± 0.5 0.42 ± 0.3 0.43 ± 0.6
Blood urea nitrogen (mg/dL) 27.3 ± 19.4 25.7 ± 18.2 30.8 ± 20.4
Serum creatinine (mg/dL) 2.5 ± 1.6 2.4 ± 1.2 2.6 ± 1.7
Serum albumin (g/dL) 2.6 ± 1.7 2.5 ± 1.8 2.6 ± 1.5
Mean arterial blood pressure (mmHg) 72.6 ± 11.6 71.8 ± 12.4 72.1 ± 14.2
Hypertension (n, (%)) 33 (10.3) 14 (9.1) 19 (11.4)
Reference GFR (mL/min/1.73 m2) 60.5 ± 33.4 54.6 ± 31.8 62.3 ± 28.7
Reference GFR by category of CKD (n, (%))
   G1 (eGFR ≥ 90  mL/min/1.73 m2) 77 (24.1) 35 (22.7) 42 (25.3)
   G2 (eGFR 60–89 mL/min/1.73 m2) 62 (19.4) 34 (22.1) 28 (16.9)
   G3a (eGFR 45–59 mL/min/1.73 m2) 49 (15.3) 22 (14.3) 27 (16.3)
   G3b (eGFR 30–44 mL/min/1.73 m2) 69 (21.5) 31 (20.1) 38 (22.9)
   G4 (eGFR 15–29 mL/min/1.73 m2) 38 (11.9) 20 (13.0) 18 (10.8)
   G5 (eGFR < 15  mL/min/1.73 m2) 25 (7.8) 12 (7.8) 13 (7.8)
Types of primary malignancy (n, (%))
   Solid malignancy 299 (93.4) 146 (94.8) 153 (92.2)
   Hematologic malignancy 21 (6.6) 8 (5.2) 13 (7.8)
Stages of malignancy (n, (%))
   Stage 1 164 (51.3) 87 (56.5) 77 (46.4)
   Stage 2 139 (43.4) 61 (39.6) 78 (47.0)
   Stage 3 17 (5.3) 6 (3.9) 11 (6.6)
   Stage 4 0 (0) 0 (0) 0 (0)

Data are shown as the mean ± SD unless otherwise specified.

BMI, body mass index; BSA, body surface area; CKD, chronic kidney disease.